JP2016526574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526574A5 JP2016526574A5 JP2016525817A JP2016525817A JP2016526574A5 JP 2016526574 A5 JP2016526574 A5 JP 2016526574A5 JP 2016525817 A JP2016525817 A JP 2016525817A JP 2016525817 A JP2016525817 A JP 2016525817A JP 2016526574 A5 JP2016526574 A5 JP 2016526574A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- nhs
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- JOGKWALAFPNFPR-VURMDHGXSA-N (4Z)-cycloocta-1,4-diene Chemical group [CH]1CC\C=C/CC=C1 JOGKWALAFPNFPR-VURMDHGXSA-N 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 3
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N Coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000004676 glycans Polymers 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 150000004804 polysaccharides Polymers 0.000 claims 2
- 101700024603 ANNU Proteins 0.000 claims 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 1
- 101700034322 TGAS Proteins 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 229960000956 coumarin Drugs 0.000 claims 1
- 235000001671 coumarin Nutrition 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000000813 microbial Effects 0.000 claims 1
- 102000035365 modified proteins Human genes 0.000 claims 1
- 108091005569 modified proteins Proteins 0.000 claims 1
- 101700012968 tgl Proteins 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
Claims (17)
- タンパク質を修飾するための方法であって:
少なくとも1つのリジン残基を有するターゲットタンパク質を提供し;
微生物トランスグルタミナーゼの存在下で、式R1−(Leu)x−Gln−(Gly)y−(A−W−B−R2)zを有する修飾化合物とターゲットタンパク質を接触させて修飾タンパク質を形成する工程を含む;
式中、xは0または1であり;yは0または1であり;zは0または1であり;
R1は:アセチル、
式中、各R4は、−H、−N3、および
Wは:約40〜約80,000amuの間の分子量を有するC1−C6直鎖または分枝鎖アルキルまたはポリエチレングリコールより選択され;
Aは、存在しないか、または−O−、−NH−、および−S−より選択され;
Bは、存在しないか、または−O−、−C(O)−、−NH−、−C(O)NH−、−NHC(O)−、−NHC(O)O−、−OC(O)NH−、−OC(O)O−、−C=N(OH)−、−S(O2)−、−NHS(O2)−、−S(O2)NH−、−S(O)−、−NHS(O)−、−S(O)NH−;−C(O)O−、−OC(O)−、−S−、=NH−O−、=NH−NH−および=NH−N(C1−C20アルキル)−より選択され;
R2は:脂肪酸、直鎖または分枝鎖C1−C3アルキル−N3、シクロオクチニル、多糖、−CH(OCH3)2、
各nは0〜6より独立に選択される整数であり;
各QはHおよびNO2より選択される
前記方法。 - 式R1−(Leu)x−Gln−(Gly)y−(A−W−B−R2)zの化合物であって、
式中、xは0または1であり;yは0または1であり;zは0または1であり;
R1は:
式中、R4は、−H、−N3、および
Wは:約40〜約80,000amuの間の分子量を有するC1−C6直鎖または分枝鎖アルキルまたはポリエチレングリコールより選択され;
Aは存在しないか、または−O−、−NH−、および−S−より選択され;
Bは存在しないか、または−O−、−C(O)−、−NH−、−C(O)NH−、−NHC(O)−、−NHC(O)O−、−OC(O)NH−、−OC(O)O−、−C=N(OH)−、−S(O2)−、−NHS(O2)−、−S(O2)NH−、−S(O)−、−NHS(O)−、−S(O)NH−;−C(O)O−、−OC(O)−、−S−、=NH−O−、=NH−NH−および=NH−N(C1−C20アルキル)−より選択され;
R2は:脂肪酸、直鎖または分枝鎖C1−C3アルキル−N3、シクロオクチニル、多糖、−CH(OCH3)2、
各nは、0〜6より独立に選択される整数であり;
そして各QはHおよび−NO2より選択される
前記化合物。 - Wが、約40〜約80,000amuの間の分子量を有するポリエチレングリコールである、請求項2の化合物。
- R 2 が脂肪酸である、請求項2の化合物。
- 式R 1 −(Leu) x −Gln−(Gly) y −(A−W−B−R 2 ) z の化合物であって、
式中、xは0または1であり;yは0または1であり;zは0または1であり;
R 1 は:
式中、R 4 は、−H、−N 3 、および
Wは約40〜約80,000amuの間の分子量を有するポリエチレングリコールであり;
Aは存在しないか、または−O−、−NH−、および−S−より選択され;
Bは存在しないか、または−O−、−C(O)−、−NH−、−C(O)NH−、−NHC(O)−、−NHC(O)O−、−OC(O)NH−、−OC(O)O−、−C=N(OH)−、−S(O 2 )−、−NHS(O 2 )−、−S(O 2 )NH−、−S(O)−、−NHS(O)−、−S(O)NH−;−C(O)O−、−OC(O)−、−S−、=NH−O−、=NH−NH−および=NH−N(C 1 −C 20 アルキル)−より選択され;
R 2 はフルオロフォアであり;
各nは、0〜6より独立に選択される整数であり;
そして各QはHおよび−NO 2 より選択される
前記化合物。 - フルオロフォアが、フルオレセイン、ローダミン、Cy色素、Alexa色素、およびクマリンからなる群より選択される、請求項7の化合物。
- 請求項2〜10のいずれか一項の化合物のコンジュゲート。
- コンジュゲートタンパク質がCRM197である、請求項11のコンジュゲート。
- コンジュゲートタンパク質がGBS80である、請求項11のコンジュゲート。
- 請求項11〜13のいずれか一項のコンジュゲートを含むワクチン。
- 請求項2〜10のいずれか一項の化合物を含む、療法タンパク質。
- 請求項2〜10のいずれか一項の化合物を含む、画像化剤。
- 請求項2〜10のいずれか一項の化合物を含む、標識ツール。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361845273P | 2013-07-11 | 2013-07-11 | |
US61/845,273 | 2013-07-11 | ||
US201462016044P | 2014-06-23 | 2014-06-23 | |
US62/016,044 | 2014-06-23 | ||
PCT/US2014/046409 WO2015006728A2 (en) | 2013-07-11 | 2014-07-11 | Site-specific chemoenzymatic protein modifications |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016526574A JP2016526574A (ja) | 2016-09-05 |
JP2016526574A5 true JP2016526574A5 (ja) | 2017-08-24 |
JP6739333B2 JP6739333B2 (ja) | 2020-08-12 |
Family
ID=51298955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016525817A Active JP6739333B2 (ja) | 2013-07-11 | 2014-07-11 | 部位特異的化学酵素的タンパク質修飾 |
Country Status (12)
Country | Link |
---|---|
US (4) | US9359400B2 (ja) |
EP (2) | EP3613755A1 (ja) |
JP (1) | JP6739333B2 (ja) |
KR (1) | KR20160040556A (ja) |
CN (1) | CN105593238B (ja) |
AU (1) | AU2014286990A1 (ja) |
BR (1) | BR112016000585A2 (ja) |
CA (1) | CA2918076A1 (ja) |
EA (1) | EA201690205A1 (ja) |
ES (1) | ES2756526T3 (ja) |
MX (1) | MX2016000393A (ja) |
WO (1) | WO2015006728A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160040556A (ko) | 2013-07-11 | 2016-04-14 | 노파르티스 아게 | 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형 |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
US11135304B2 (en) * | 2015-12-18 | 2021-10-05 | Eisai R&D Management Co., Ltd. | C-terminal lysine conjugated immunoglobulins |
EP3436061A4 (en) | 2016-03-31 | 2019-12-04 | Liffey Biotech Limited | Saccharide-polypeptide-conjugate compositions and methods of use thereof |
SG11201810470XA (en) * | 2016-06-10 | 2018-12-28 | Eisai R&D Man Co Ltd | Lysine conjugated immunoglobulins |
SG11201901394XA (en) | 2016-09-02 | 2019-03-28 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
WO2023244963A2 (en) * | 2022-06-16 | 2023-12-21 | The General Hospital Corporation | Bicyclononyne reagents for cell imaging |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
DE4022267C2 (de) * | 1990-07-12 | 1994-09-15 | Degussa | N-Acyldipeptide und deren Verwendung |
JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
DK0658118T3 (da) | 1992-08-31 | 2002-05-06 | Baxter Healthcare Sa | Vaccine mod Neisseria meningitidis, gruppe C |
US5508191A (en) | 1993-07-05 | 1996-04-16 | Takeda Chemical Industries, Ltd. | Mutant strains of agrobacterium for producing β-1,3-glucan |
NZ291414A (en) | 1994-08-26 | 1998-05-27 | Novo Nordisk As | Microbial transglutaminases and methods of production using fungi and dna constructs |
EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
ATE248219T1 (de) | 1995-01-19 | 2003-09-15 | Novozymes As | Transglutaminasen aus oomyzeten |
JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
US6284884B1 (en) | 1995-06-07 | 2001-09-04 | North American Vaccine, Inc. | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
EP0815833B1 (en) * | 1996-06-24 | 2003-04-09 | Givaudan SA | Malodour preventing agents |
WO1998013381A1 (fr) | 1996-09-26 | 1998-04-02 | Ajinomoto Co., Inc. | Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
US6958148B1 (en) | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
US6267957B1 (en) | 1998-01-20 | 2001-07-31 | Howard Green | Attaching agents to tissue with transglutaminase and a transglutaminase substrate |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
EP2332581B1 (en) | 2001-01-23 | 2015-07-01 | Sanofi Pasteur Inc. | Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine |
US7605175B2 (en) | 2001-03-02 | 2009-10-20 | Gpc Biotech Ag | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
PT1490409E (pt) | 2002-03-26 | 2009-04-03 | Novartis Vaccines & Diagnostic | Sacáridos modificados possuindo uma estabilidade melhorada em água |
GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
US20080019918A1 (en) | 2004-09-10 | 2008-01-24 | Takao Aoki | Medicinal Preparation |
US7858101B2 (en) | 2004-11-01 | 2010-12-28 | The Brigham And Women's Hospital, Inc. | Modified streptococcal polysaccharides and uses thereof |
GB0502096D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
CA2612794A1 (en) * | 2005-06-15 | 2006-12-21 | Novo Nordisk Health Care Ag | Transglutaminase mediated conjugation of growth hormone |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
CN101809032A (zh) * | 2007-08-24 | 2010-08-18 | 诺沃-诺迪斯克有限公司 | 用于选择性修饰蛋白质的方法 |
WO2009032247A1 (en) * | 2007-08-30 | 2009-03-12 | Northwestern University | Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme |
DE102007044296A1 (de) * | 2007-09-17 | 2009-03-19 | Hans-Lothar Prof. Dr. Fuchsbauer | Strukturmodulator von Proteinen |
US8137925B2 (en) * | 2007-11-09 | 2012-03-20 | Massachusetts Institute Of Technology | Methods and compositions for protein labeling using lipoic acid ligases |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
US20110184147A1 (en) | 2008-07-04 | 2011-07-28 | Kyushu University, National University Corporation | Enzyme substrate for labeling of protein |
CN102333788A (zh) * | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
US8853151B2 (en) | 2009-06-30 | 2014-10-07 | The Regents Of The University Of Michigan | Pro-drug complexes and related methods of use |
US20110020837A1 (en) | 2009-07-07 | 2011-01-27 | Universiteit Utrecht Holding B.V. | Method for isolating or identifying a target protein interacting with a lipid in a cell |
CA2785410A1 (en) | 2009-12-23 | 2011-06-30 | Carlos F. Barbas, Iii | Tyrosine bioconjugation through aqueous ene-like reactions |
CN103153927B (zh) | 2010-04-27 | 2017-02-15 | 西纳福克斯股份有限公司 | 稠合的环辛炔化合物及其在无金属点击反应中的应用 |
EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590989A2 (en) | 2010-07-09 | 2013-05-15 | Universite de Bretagne Occidentale | Modular construction of lipophospholipids |
WO2012058635A1 (en) | 2010-10-29 | 2012-05-03 | Life Technologies Corporation | Biotin derivatives |
US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
WO2012078559A2 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
CA2814953A1 (en) | 2010-12-13 | 2012-06-21 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
FR2981352B1 (fr) * | 2011-10-17 | 2015-07-03 | Centre Nat Rech Scient | Procede de synthese de proteines |
US20150037311A1 (en) | 2011-12-01 | 2015-02-05 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
JP5509440B2 (ja) * | 2012-06-22 | 2014-06-04 | 国立大学法人九州大学 | タンパク質−核酸複合体の製造方法および標的物の検出方法 |
KR20160042871A (ko) * | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
KR20160040556A (ko) | 2013-07-11 | 2016-04-14 | 노파르티스 아게 | 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형 |
-
2014
- 2014-07-11 KR KR1020167003053A patent/KR20160040556A/ko not_active Application Discontinuation
- 2014-07-11 EA EA201690205A patent/EA201690205A1/ru unknown
- 2014-07-11 US US14/329,758 patent/US9359400B2/en active Active
- 2014-07-11 BR BR112016000585A patent/BR112016000585A2/pt not_active Application Discontinuation
- 2014-07-11 CA CA2918076A patent/CA2918076A1/en not_active Abandoned
- 2014-07-11 EP EP19187438.7A patent/EP3613755A1/en not_active Withdrawn
- 2014-07-11 AU AU2014286990A patent/AU2014286990A1/en not_active Abandoned
- 2014-07-11 CN CN201480046805.8A patent/CN105593238B/zh active Active
- 2014-07-11 EP EP14748350.7A patent/EP3019515B1/en active Active
- 2014-07-11 WO PCT/US2014/046409 patent/WO2015006728A2/en active Application Filing
- 2014-07-11 JP JP2016525817A patent/JP6739333B2/ja active Active
- 2014-07-11 ES ES14748350T patent/ES2756526T3/es active Active
- 2014-07-11 MX MX2016000393A patent/MX2016000393A/es unknown
-
2016
- 2016-05-02 US US15/144,397 patent/US20160237116A1/en not_active Abandoned
-
2018
- 2018-11-29 US US16/204,557 patent/US10975120B2/en active Active
-
2021
- 2021-04-12 US US17/228,284 patent/US20220089639A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016526574A5 (ja) | ||
JP2016153410A5 (ja) | ||
JP2013510120A5 (ja) | ||
JP2010527913A5 (ja) | ||
JP2017523225A5 (ja) | ||
JP2016065060A5 (ja) | ||
JP2020507589A5 (ja) | ||
MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
JP2016505586A5 (ja) | ||
RU2015146614A (ru) | Конъюгированная вакцина на основе пептида антигена wt1 | |
AR099134A1 (es) | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina | |
JP2014511891A5 (ja) | ||
JP2012518029A5 (ja) | ||
JP2012017342A5 (ja) | ||
JP2016130266A5 (ja) | ||
JP2018531987A5 (ja) | ||
JP2012513416A5 (ja) | ||
AR070352A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto. | |
JP2016503797A5 (ja) | ||
JP2016506386A5 (ja) | ||
JP2013514329A5 (ja) | ||
RU2008131311A (ru) | Производные тритерпенхинона и тритерпенфенола и их применение для лечения опухолей и паразитарных заболеваний | |
JP2011137045A5 (ja) | ||
JP2015528463A5 (ja) | ||
JP2014508804A5 (ja) |